Navigation Links
BioNeutral's Ygiene(TM) Hospital Grade Achieves World Class Independent Test Results in Killing Life Threatening Spores/Organisms

NEWARK, N.J., July 13 /PRNewswire-FirstCall/ -- BioNeutral Group, Inc. ("BioNeutral") (OTC Bulletin Board: BONU), a specialty chemical technology-based Life Science company announced today that at ATS Labs using the EPA required AOAC Sporicidal Test, the Hospital Grade of its Ygiene(TM) formula produced a 100% Total Kill of live spores in seven (7) minutes. This EPA required AOAC Sporicidal Test utilizing spore impregnated then knotted suture loops and porous cylinders is an extremely difficult test to pass, especially when starting with over one million Clostridium Sporogenes spores. The rapid elimination of these health threatening microorganisms, in the spore form, at health care facilities will reduce the incidents of Hospital Acquired Infections (HAI) and the associated loss of lives. From one million spores to zero in 7 minutes is up to 50 times faster than the competition. This means money and lives saved at every health care facility around the world.

Examples of commonly used antimicrobials in health care facilities including hospitals which cannot claim passing this EPA sporicide/sterilant test include CaviCide(R), Medica DC 10(TM), Wavicide 06 Plus(TM) and Myacide(R) GA 25. While these antimicrobials may eliminate easily eradicated bacteria and some viruses, they have no effect on spores and therefore cannot provide truly disinfected and sterile environments in the health care arena. Examples of antimicrobials which have passed the EPA required test include Steris(R) Hydrogen Peroxide Sterilant. However, special protective equipment and highly trained professionals are required to correctly apply this antimicrobial. In addition this product takes a full 90 minutes of direct contact to eliminate spores. In comparison while Steris(R) Spor-Klenz RTU may be easier to apply, it can take up to 5.5 hours to eliminate spores. These currently used commercial products have significant shortcomings by being ineffective, cumbersome to use or require very lengthy periods of time to be effective at all in eliminating health threatening spores.

A room temperature, cold, sporicide/sterilant with the rapid kill demonstrated by Ygiene(TM) Hospital Grade will provide a huge economic advantage for future users. By delivering a safe easy to use and a much quicker turn around time for total sterilization of equipment and facilities, BioNeutrals Ygiene(TM) will greatly reduce the waste of human resources and capital currently experienced in health care facilities and will maximize value to the user & increased safety for the patients.

Dr. Andy Kielbania PhD, Chief Scientist at BioNeutral Group stated: "These independent lab validation results from ATS show that we have developed what we believe is the best, and I emphasize the best, antimicrobial coming to the market. By using the strategy of raising the bar for antimicrobial performance, we believe our superior Ygiene(TM) Hospital Grade antimicrobial will provide much cleaner, safer and healthier environments in health care facilities globally. Reducing the loss of lives and wasteful expenditures of human resources and money by diminishing Hospital Acquired Infections (ACI) is our goal. These independent test results stand by themselves and are consistent with our achieving our goals and objectives. These results are incredible and validate all of our efforts."

Dr. Philip M. Tierno Jr. MS, PhD Chairman of BioNeutral Group Scientific Advisory Board stated: "The sporocidal data on Ygiene(TM)'s performance that I reviewed is quite impressive. Two immediate and important applications of Ygiene(TM) come to mind:

1- Perhaps the biggest challenge facing hospitals worldwide is eradication of Clostridium difficile spores in the environment in a timely fashion thereby reducing or eliminating possible nosocomial spread. Ygiene(TM) safely and efficiently solves that problem.

2- The safe, rapid and effective killing of all multi-antibiotic drug resistant pathogenic bacteria like MRSA, VRE, ESBL, AmpC, KPC, etc in the hospital environment is again easily accomplished by Hospital Grade Ygiene(TM). In short, having met the EPA's AOAC Sporocidal Test standard in such a timely fashion is an impressive and significant accomplishment."

"Killing these extremely dangerous microorganisms on a flat non-porous surface is one thing. Having now proven that our Hospital Grade Ygiene(TM) can hunt them down and kill them where ever they may hide is something else entirely" said Stephen J. Browand CEO BioNeutral Group Inc. "These test results along with a number of others soon to be announced will bring our various formulations to the forefront of scientific breakthroughs discovered in this millennium. All of our technology was developed under the mantra of creating science to not only save lives but also protect the environment; this formula falls well within those guidelines."

About ATS Labs:

ATS Labs, is a leading internationally recognized lab used by the developers and users of antimicrobial products. They provide comprehensive antimicrobial service and their superior client service and scientific data have earned them a distinguished record of acceptance with regulatory agencies in the U.S., Canada and the world.

About BioNeutral Group, Inc.

Headquartered at the New Jersey Institute of Technology/EDC in Newark, New Jersey, BioNeutral Group, Inc., is a chemical technology-based Life Science company that intends to commercialize a combinational chemistry-based technology which can neutralize harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores. The formulations, including Ygiene(TM) and Ogiene(TM), which are eco-friendly and include natural and common ingredients which are found in baby products and in every day foods. The Company has combined these widely-used compounds in highly specialized ways to create products that dramatically enhance disinfecting and cleaning results; products include BioNeutralizers and ChemoNeutralizers. BioNeutral's proprietary platform technology has been proven effective in surface, water and airborne applications.

More information about the Company may be found at

Forward-Looking Statements

BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how the Company's technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA and FDA have not reviewed or confirmed the Company's data and findings. BioNeutral's antimicrobial formulations will be marketed under the brand name Ygiene(TM) and are not yet available for sale in the United States.

SOURCE BioNeutral Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. BioNeutrals Ygiene(TM) Hospital Grade Antimicrobial Demonstrates a 99.9997% Kill Rate Against Clostridium Difficile Spores (C.diff) in Independent Lab Pre-testing Phase
2. BioNeutrals Ygiene(TM) New Hospital Grade Disinfectant Will Save Lives and Billions of Dollars Annually at Health Care Facilities Around the World
3. Stem Cell Cord Blood Banking Is Huge Global Business for Hospitals, Says CEO of Bio-Matrix Scientific Group Inc.
4. Galichia Heart Hospital Partners with Mobile Surgery International to Develop Wichita-based Center of Excellence with Global Convenience(TM)
5. GeoVax Signs HIV/AIDS Vaccine Proposal With Health and Hospital System of Cook County, Illinois
6. Cumberland Pharmaceuticals Provides Hospital In-Service Webcast for Acetadote(R)
7. Fate Therapeutics Granted Exclusive License for Stem Cell Modulators by Childrens Hospital Boston and Massachusetts General Hospital
8. CPM Resource Center and The Shams Group Partner To Help Hospitals Integrate Evidence-Based Clinical Content Into Information Systems
9. University of Illinois Medical Center in Chicago First Hospital to Install Innovative Shape-HF™ Cardiopulmonary Testing System
10. New Hospital Energy Performance Service Helps Hospitals Cut Energy Costs by 25% or More
11. TeleHealth Services Chosen by Baptist Hospital East in Development of New Park Tower
Post Your Comments:
(Date:10/9/2015)... ROCKVILLE, Md. , Oct. 9, 2015 ... company developing next generation vaccines based on the ... into an exclusive worldwide licensing agreement with Astellas ... or prevention of any and all allergic diseases ... Therapeutics will receive an upfront payment of $300 ...
(Date:10/8/2015)... UK (PRWEB) , ... October 08, 2015 , ... Researchers ... literally see inside the living brain, providing a new tool to study how diseases ... is reported by Woo June Choi and Ruikang Wang of the UW Department of ...
(Date:10/8/2015)... Pa. , Oct. 8, 2015  Clarkston Consulting, ... the call for applications for the 2016 Clarkston Scholars ... a life sciences related field of study, a $10,000 ... selected Clarkston Scholar will receive exposure to the life ... in Pennsylvania Bio events over the course of the ...
(Date:10/8/2015)... , Oct. 8, 2015  Today, DuPont and ... for genome editing, jointly announced a strategic alliance. ... cross-licensed their respective patent portfolios, with DuPont receiving ... in major row crops, and non-exclusive rights in ... --> --> In ...
Breaking Biology Technology:
... RICHMOND, Va., June 20 Insmed Inc. (Nasdaq:,INSM), ... that it intends to request a hearing before ... an earlier Staff Determination,to delist the Company,s common ... received a letter from The NASDAQ Stock Market ...
... Initiated to Find Suitable Candidate, WESLEY CHAPEL, ... today that Eran Rotem, its Chief,Financial Officer, who ... June 2008. The Company has initiated search for ... this position., Ram Ajjarapu commented: "We appreciate ...
... Germany – June 20, 2008 / b3c newswire ... contract manufacturing organization (CMO) for the development and ... of a 2,500 L multi-process production suite. Hence, ... with volumes of 30, 250, 500 and 2,500 ...
Cached Biology Technology:
(Date:9/30/2015)... Sept. 30, 2015  With nearly 300,000 Americans living ... new SCIs estimated to reach 12,500 annually, the role ... Resource Services for Independent Living (SCRS-IL) is increasingly ... California opening doors to independence for ... and services, notably assistive technology services and education. ...
(Date:9/29/2015)... SUNNYVALE, Calif. , Sept. 29, 2015 ... technology improves employee productivity while also saving energy ... features such as Low Power Active Mode and embedded ... workplace transformation Fujitsu today shows that ... of new and refreshed models to its enterprise desktop ...
(Date:9/28/2015)... Sept. 28, 2015  The monitoring of vital ... body temperature, is an essential component of patient ... of deterioration in a patient,s condition. However, in ... are typically taken during routine observation rounds only ... patient deteriorates between these observation rounds, the warning ...
Breaking Biology News(10 mins):
... Comparative Biology (SICB), one of the oldest and most ... at the Hilton San Francisco, Union Square, in San ... than 1,500 scientists will present the latest research on ... a rich assortment of news and feature possibilities. ...
... in biology are given the freedom to play, dabble in ... worry about getting "good" results? In the case ... level of new knowledge and publications generated by student-and-faculty teams. ... magazine, several scientists who have directed the Physiology course detail ...
... Chinese research team, led by Beijing Forestry University, BGI, Beijing ... has completed the first genomic sequence of Prunus mume ... the deeper understanding of Rosaceae evolution and provides an invaluable ... was published online today in Nature Communication ., As ...
Cached Biology News:
Rabbit polyclonal to Olfactory Receptor LS189744 ( Abpromise for all tested applications)....
Recognizes the VZV nucleocapsid by indirect immunofluorescence and immunoprecipitation. Shows cross-reactivity to HSV....
Mouse monoclonal [11C9] to Zeralenone ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule conjugated to BSA: Zeralenone...
AK6 Antibody...
Biology Products: